Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

NEXT STORY
Advanced Wound Dressings Market to Reach US$ 8,460.8 Mn by 2025, Increasing FDA Approvals to Enable Growth, says Fortune Business Insights
PREV STORY
RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

author_avatar
NASDAQ Market News

Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market

   PRESS RELEASE                                                                             7 January 2019, 07:00 CET Biocartis and Nichirei Bioscience Announce ...

author_avatar
NASDAQ Market News

Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements

Madrigal’s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session ...

author_avatar
NASDAQ Market News